JFJaviera Fuenzalida

Javiera Fuenzalida

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Javiera Fuenzalida has a total of 136 co-authors. Here are the top co-authors by number of shared publications:

  • Jan Deprest

    UCL Elizabeth Garrett Anderson Institute for Women's Health University College London London UK

    3 shared publications
  • Adriana Gomes Luz

    Universidade Estadual de Campinas Faculdade de Ciências Médicas CampinasSP Brazil Faculdade de Ciências Médicas, Universidade Estadual de Campinas, Campinas, SP, Brazil

    2 shared publications
  • Albaro José Nieto Calvache

    Fundacion Clinica Valle de Lili, Universitary Hospital

    2 shared publications
  • Alejandra Abascal

    Hospital Universitario La Paz

    2 shared publications
  • Alice Panchaud

    Center for Research and Innovation in Clinical Pharmaceutical Sciences, Institute of Pharmaceutical Sciences of Western Switzerland, Lausanne University Hospital and University of Geneva; Service of Pharmacy, Lausanne University Hospital

    2 shared publications
  • Amanda Dantas-Silva

    Department of Obstetrics and Gynecology Universidade Estadual de Campinas São Paulo Brazil

    2 shared publications

Latest Publications

  • Intrapulmonary artery Doppler to predict mortality and morbidity in fetuses with mild or moderate left‐sided congenital diaphragmatic hernia

    by D. Basurto, J. Fuenzalida, R. J. Martinez‐Portilla, F. M. Russo, A. Pertierra, J. M. Martínez, J. Deprest, E. Gratacós, O. Gómez

    Objectives: In fetuses with isolated left‐sided congenital diaphragmatic hernia (LCDH), prenatal detection of severe pulmonary hypoplasia is important, as fetal therapy can improve survival. Cases with mild or moderate lung hypoplasia still carry a considerable risk of mortality and morbidity, but there has been less interest in the accurate prediction of outcome in these cases. In this study of fetuses with mild or moderate isolated LCDH, we aimed to investigate: (1) the association between intrapulmonary artery (IPA) Doppler findings and mortality at discharge; (2) whether adding IPA Doppler findings improves the prediction of mortality based on lung size and liver herniation; and (3) the association between IPA Doppler findings and early neonatal morbidity.Methods: This was a retrospective study of all consecutive fetuses assessed at the BCNatal and UZ Leuven hospitals between 2008 and 2020 with a prenatal diagnosis of isolated, non‐severe LCDH, defined as observed‐to‐expected lung‐to‐head ratio (o/e‐LHR) > 25%, that were managed expectantly during pregnancy followed by standardized neonatal management. An additional inclusion criterion was the availability of IPA Doppler measurements. The primary outcome was the association between IPA Doppler findings and mortality at discharge. Other predictors included o/e‐LHR, liver herniation and gestational age at birth. Secondary outcomes were the association between IPA Doppler findings and the presence of pulmonary hypertension (PHT), need for supplemental oxygen at discharge and need for extracorporeal membrane oxygenation. IPA pulsatility index (PI) values were converted into Z‐scores. Logistic regression analysis was performed to investigate the associations between predictor variables and outcome, and the best model was chosen based on the Nagelkerke R2.Results: Observations for 70 non‐severe LCDH cases were available. Fifty‐four (77%) fetuses survived until discharge. On logistic regression analysis, higher IPA‐PI was associated with an increased risk of mortality (odds ratio (OR), 3.96 (95% CI, 1.62–9.70)), independently of o/e‐LHR (OR, 0.87 (95% CI, 0.79–0.97)). An IPA‐PI Z‐score cut‐off of 1.8 predicted mortality with a detection rate of 69% and specificity of 93%. Adding IPA‐PI to o/e‐LHR improved significantly the model's performance (Nagelkerke R2, 46% for o/e‐LHR + IPA‐PI vs 28% for o/e‐LHR (P < 0.002)), with a detection rate of 81% at a 10% false‐positive rate. IPA‐PI was associated with PHT (OR, 2.20 (95% CI, 1.01–4.59)) and need for oxygen supplementation at discharge (OR, 1.90 (95% CI, 1.10–3.40)), independently of lung size.Conclusions: In fetuses with mild or moderate LCDH, IPA‐PI was associated with mortality and morbidity, independently of lung size. A model combining o/e‐LHR with IPA‐PI identified up to four in five cases that eventually died, despite being considered to have non‐severe pulmonary hypoplasia. © 2021 International Society of Ultrasound in Obstetrics and Gynecology.


  • Open Access

    Maternal Outcomes and Risk Factors for Severity Among Pregnant Women With COVID-19: A Case Control Study From the COVI-Preg International Registry

    by Manon Vouga, Guillaume Favre, Oscar Martinez Perez, Leo Pomar, Laura Forcen Acebal, Alejandra Abascal, Maria Rosa Vila Hernandez, Najeh Hcini, Véronique Lambert, Gabriel Carles, et al.

    Background: Recent evidence suggests that pregnant women might be at higher risk of severe disease associated with the emerging pandemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), while exposed fetuses/newborns could suffer from preterm birth, growth restriction and neonatal infections. The magnitude of this increased risk and specific risk factors for severity remains unclear. Methods: We performed a case control study comparing pregnant women with severe coronavirus disease 19 (case) to pregnant women with a milder form (controls) enrolled in COVI-Preg international registry cohort between from March 24 to July 26, 2020. Risk factors for severity, obstetrical, fetal and neonatal outcomes were assessed. Findings: A total of 926 pregnant women with a positive test for SARS-CoV-2 were included, among which 92 (9.9%) presented a severe COVID-19 disease. Risk factors for severe maternal outcomes were pulmonary comorbidities [aOR 4.3, 95% CI 1.9-9.5], hypertensive disorders [aOR 2.7, 95% CI 1.0-7.0] and diabetes [aOR2.2, 95% CI 1.1-4.5]. Pregnant women with severe maternal outcomes were at higher risk of cesarean sections [70.7% (n=53/75)], preterm deliveries [62.7% (n= 32/51)] and newborns requiring admission to the neonatal intensive care unit [41.3% (n=31/75)]. Interpretation: Pregnant women, particularly those with associated comorbidities, seem to be at higher risk of severe complications of SARS-CoV-2 infection. Obstetrical and neonatal outcomes appear to be influenced by the severity of maternal disease; complications include cesarean sections, prematurity and neonatal admission to the intensive care unit. Funding Statement: None. Declaration of Interests: The authors declare that they have no conflicts of interest. Ethics Approval Statement: The study was approved by both the Swiss Ethical Board (CER-VD- 2020-00548) and the local ethics boards at each participating center.

  • Open Access

    Maternal and Obstetrical Outcomes in a Cohort of Pregnant Women Tested for SARS-CoV-2: Interim Results of the COVI-Preg International Registry

    by Manon Vouga, Guillaume Favre, Oscar Martinez Perez, Leo Pomar, Laura Forcen Acebal, Alejandra Abascal, Maria Rosa Vila Hernandez, Najeh Hcini, Véronique Lambert, Gabriel Carles, et al.

    Background: Pregnant women represent a vulnerable population at higher risk of complications of infectious diseases. Data regarding the consequences of the emerging pandemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during pregnancy are scarce. Recent evidence suggests that pregnant women might be at higher risk of severe disease, while exposed fetuses and newborns could suffer from preterm birth, growth restriction and neonatal infections. Methods: We developed an international web registry to allow structured data collection. Pregnant women at any stage during gestation tested for SARS-CoV-2 infection were enrolled. Maternal, obstetrical and neonatal outcomes were recorded. Findings: 1033 pregnant women tested for SARS-CoV-2 were included, among which 926 tested positive and 107 tested negative. Positive pregnant women were at higher risk of severe maternal outcomes compared to negative women [aRR 5.6, 95% CI 1.4-22.7]. Risk factors for severe maternal outcomes among positive women were pulmonary comorbidities [aOR 4.3, 95% CI 1.9-9.5], hypertensive disorders [aOR 2.7, 95% CI 1.0-7.0] and diabetes [aOR2.2, 95% CI 1.1-4.5]. No difference in term of obstetrical and neonatal outcomes were observed between positive and negative women. Positive pregnant women with severe maternal outcomes were at higher risk of cesarean sections [70.7% (n=53/75)], preterm deliveries [62.7% (n= 32/51)] and newborns requiring admission to the neonatal intensive care unit [41.3% (n=31/75)]. A positive neonatal SARS-CoV-2 test was observed in 2.9% (n=11/384) of newborns with an available test at birth. Interpretation: Pregnant women, particularly those with associated comorbidities, seem to be at higher risk of severe complications of SARS-CoV-2 infection. Preliminary data regarding obstetrical and neonatal outcomes among women with a mild disease are reassuring. Funding Statement: None. Declaration of Interests: The authors declare that we have no conflicts of interest. Ethics Approval Statement: The study was approved by both the Swiss Ethical Board (CER-VD-2020-00548) and the local ethics boards at each participating center.